Canadian clinical-stage psychedelics company Cybin Inc. (NYSE: CYBN) announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing three-part Phase 1 trial evaluating both intravenous DMT and CYB004 in healthy volunteers. 

CYB004’s robust psychedelic effects were seen within two minutes of administration, reaching a peak at about thirteen minutes. No safety concerns were reported from the dosed group.

Part 3 (C) of the Phase 1 trial has a crossover design set to evaluate IV bolus plus infusion regimens of CYB004 in up to two cohorts. Together with completed Part B, they are expected to provide a comprehensive PK/PD model toward determining optimal dosing and formulation for following trials on the proprietary drug. 

Cybin anticipates a safety …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.